Drug strategies and treatment-resistant schizophrenia

Australian and New Zealand Journal of Psychiatry

Volumn 30, Issue 1, 1996, Pages 20-37

  Pantelis, Christos ^a,c   Barnes, Thomas R E ^b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CARPIPRAMINE; CHLORDIAZEPOXIDE; CLOCAPRAMINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LITHIUM; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PIQUINDONE; QUETIAPINE; REMOXIPRIDE; RESERPINE; RISPERIDONE; ZOTEPINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; ATAXIA; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MEGADOSE; DRUG RESPONSE; DYSTONIA; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MOTOR DYSFUNCTION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOPHRENIA; SEDATION; SINGLE BLIND PROCEDURE; SUBSTANCE ABUSE;

EID: 0029869847     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679609076070     Document Type: Article

References (184)

1. Davis JM, Casper R, Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977,14:260-282.
2. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990, 16:551-562.
3. Keks NA, Copolov DL, Johnson G. Initial Australian experience with the atypical antipsychotic clozapme. Medical Journal of Australia 1993: 159:638-639.
4. Kane JM. Treatment of schizophrenia. Schizophrenia Bulletin 1987; 13:133-156.
5. Brown WA, Herz LR. Response to neuroleptic drugs as a device for classifying schizophrenia. Schizophrenia Bulletin 1989; 15:123-129.
6. Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990; 16:563-565.
7. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophrenia Bulletin 1980; 6.70-87.
8. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45:789-796.
9. May PRA. Treatment of schizophrenia: a comparative study of five treatment methods. New York: Science House, 1968.
10. MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. III. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986; 148:128-133
11. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991; 48:239-246. [Published erratum appears in Archives of General Psychiatry 1991; 48:642.]
12. May PRA, Dencker SJ, Hubbard JW, Midha KK, Liberman RP. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, eds. Treatment resistance in schizophrenia. Braunschweig: Friedr. Vieweg Verlag, 1988:22-23.
13. Linszen DH, Dingemans PM, Lenior ME. Cannabis use and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994; 51:273-279.
14. Smith J, Hucker S. Schizophrenia and substance abuse British Journal of Psychiatry 1994; 165:13-21.
15. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance. Psychiatric Annals 1986; 16:571-575.
16. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 1990; 41:1203-1211.
17. Mann JJ. How medication compliance affects outcome. Psychiatric Annals 1986; 16:567-570.
18. Kane JM Prevention and treatment of neuroleptic noncompliance. Psychiatric Annals 1986; 16:576-578.
19. Gaebel W, Pietzcker A. Prospective study of course of illness in schizophrenia. Part III: treatment and outcome. Schizophrenia Bulletin 1987; 13:307-316.
20. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Archives of General Psychiatry 1990; 47:228-236.
21. Quitkin F, Rifkin A, Kane JM, Ramos-Lorenzi J, Klein D. Long-acting oral vs injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry 1978; 35:889-892.
22. Falloon I, Watt DC, Shepherd M. A comparative control trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine 1978; 8:59-70
23. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic outpatients: the seven-year follow-up of the MRC fluphenazine/placebo trial. British Journal of Psychiatry 1985; 146:464-480.
24. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? British Medical Journal 1980; 280:66-68.
25. Johnstone EC, Crow TJ, Frith CD, Camey WMP, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978; i:848-851.
26. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bulletin 1985; 11:453-456.
27. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry 1987; 144:1549-1555.
28. Barnes TRE Issues in the clinical assessment of negative symptoms: editorial review. Current Opinion in Psychiatry 1994; 7.35-38.
29. van-Kammen DP, Hommer DW, Malas KL. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? Neuropsychobiology 1987; 18:113-117.
30. Feinberg SS, Kay SR, Elijovich LR, Fiszbein A, Opler LA. Pimozide treatment of the negative schizophrenic syndrome: an open trial. Journal of Clinical Psychiatry 1988; 49:235-238.
31. Petit M, Zami M, Lesieur P, Colonna L. The effect of sulpiride on negative symptoms of schizophrenia [letter]. British Journal of Psychiatry 1987, 150:270-271.
32. Barnes TRE, Speller JC, Curson DA, Pantelis C, Alberts JL. A one-year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol. Schizophrenia Research 1992; 6:107 (abstract).
33. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 1995; 166:68-72.
34. Kane JM. Mayerhoff D Do negative symptoms respond to pharmacological treatment? British Journal of Psychiatry 1989; 155 (suppl. 7): 115-118.
35. Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride - a combined analysis of a comparative double blind multicentre trial programme. Acta Psychiatrica Scandinavica 1990; 82(suppl. 358):92-98.
36. Marder SR, Meibach RC. Rispetidone in the treatment of schizophrenia, American Journal of Psychiatry 1994; 151:825-835.
37. Rey MJ, Schulz SC, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. International Clinical Psychopharmacology 1989; 4:95-104.
38. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry 1988; 145:578-583.
39. Carpenter WT Jr. The deficit syndrome. American Journal of Psychiatry 1994; 151:327-329.
40. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 1994; 151:20-26.
41. Kolakowska T, Williams AO, Arden M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptic and signs of organic dysfunction. British Journal of Psychiatry 1985; 146:229-239.
42. Murray RM, O'Callaghan E. Neurodevelopmental schizophrenia. Schizophrenia Monitor 1991; 1:1-3.
43. Castle DJ, Murray RM. The neurodevetopmental basis of sex differences in schizophrenia. Psychological Medicine 1991; 21:565-575.
44. Nelson HE, Pantelis C, Carruthers K, Speller J, Baxendale S, Barnes TRE. Cognitive functioning and symptomatology in chronic schizophrenia. Psychological Medicine 1990; 20:357-365.
45. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels Schizophrenia Bulletin 1991; 17:197-216.
46. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry 1987; 48 suppl:13-19.
47. Smith RC, Baumgartner R, Misra CH, Maudlin M. Haloperidol, plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical vs radioreceptor plasma level assay. Archives of General Psychiatry 1984; 41:1044-1049.
48. Cooper TB, Simpson GM, Haher EJ, Bergner PE. Butaperazine pharmacokinetics. Archives of General Psychiatry 1975; 32:903-905.
49. Johnstone EC, Crow TJ, Ferner IN, Frith CD, Owens DGC. Bourne RC, Gamble SJ. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine 1983; 13:513-527.
50. Kahn EM, Schulz SC, Perel JM, Alexander JE. Change in halopendol level due to carbamazepine: a complicating medication for schizophrenia. Journal of Clinical Psychopharmacology 1990; 10:54-57.
51. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991: 17:325-351.
52. Angrist B, Schulz SC. Introduction. In: Angrist B, Schulz SC, eds The neuroleptic nonresponsive patient: characterization and treatment. Washington: American Psychiatric Press. I990:xvii-xxviii.
53. Crow TJ, MacMillan JF, Johnson AL, Johnston EC. The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986; 148:120-127.
54. Dencker SJ, May PRA. From chrome mental hospital care to integration in society. In: Dencker SJ, Kulhanek F. eds. Treatment resistance in schizophrenia. Wiesbaden: S.J. Dencker and F. Kulhanek, 1988:13-21.
55. Green MF, Kinsbourne M. Subvocal activity and auditory hallucinations: clues for behavioral treatments? Schizophrenia Bulletin 1990; 16:617-625.
56. Nelson HE, Barnes TRE, Thrasher S. Practical ways of alleviating auditory hallucinations. British Medical Journal 1991;302:327.
57. Chadwick P, Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. British Journal of Psychiatry 1994; 164:190-201.
58. Kingdon D, Turkington D, John C. Cognitive behaviour therapy of schizophrenia. British Journal of Psychiatry 1994; 164:581-587.
59. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991; 17:217-245.
60. Hirsch SR, Barnes TRE. Clinical use of high-dose neuroleptics. British Journal of Psychiatry 1994; 164:94-96.
61. Kane JM. The use of higher-dose antipsychotic medication: comment on the Royal College of Psychiatists' consensus statement. British Journal of Psychiatry 1994; 164:431-432.
62. Thompson C. The use of higher-dose antipsychotic medication: consensus statement. British Journal of Psychiatry 1994; 164:448-458.
63. Itil TM, Keskiner A, Heinemann L, Han T, Gannen P, Hsu W. Treatment of resistant schizophrenia with extreme high dosage fluphenazine hydrochloride. Psychosomatics 1970; 11:436-463.
64. Quitkin F, Rifkin A, Klein DF. Very high dosage versus standard dosage fluphenazine in schizophrenia: a double-blind study of non-chronic treatment refractory patients. Archives of General Psychiatry 1975; 32:1276-1281.
65. McCreadie RG, McDonald IM. High dosage haloperidol in chronic schizophrenia. British Journal of Psychiatry 1977; 131:310-316
66. Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestruch IH, Waerens J. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side-effects, serum haloperidol, and serum prolactin Psychopharmacology 1980; 67:17-23.
67. Kinon BS, Kane JM, Johns JC, Perovich R, Ismi A, Koreen A, Weiden P. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacology Bulletin 1993; 29:309-314.
68. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly-admitted schizophrenic patients. Archives of General Psychiatry 1990; 47:754-758
69. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Archives of General Psychiatry 1991; 48:166-170.
70. McEvoy JP, Hogarty GE, Steingard S, Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshoid and higher haloperidol dose. Archives of General Psychiatry 1991; 48:739-745.
71. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry 1988; 45:79-91.
72. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. American Journal of Psychiatry 1980; 137:16-21.
73. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin 1991; 17:263-287.
74. Seeman P. Schizophrenia as a brain disease: the dopamine receptor story. Archives of Neurology 1993; 50:1093-1095.
75. Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. British Journal of Psychiatry 1993; 163:451-455.
76. Litman RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D. Idazoxan, an alpha antagonist augments fluphenazine in schizophrenic patients: a pilot study. Journal of Clinical Psychopharmacology 1993; 13:264-267.
77. Stahl SM, Wets KM. Clinical pharmacology of schizophrenia. In: Bebbington P, McGuffin P, eds. Schizophrenia: the major issues. London: Heinemann Professional Publishing/ Mental Health Foundation, 1988.
78. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin 1991; 17:289-309.
79. Meltzer HY. Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research 1994; 9:23-40.
80. Drew L. Clozapine - a remarkable drug. Australasian Psychiatry 1993; 1:156-157.
81. Kerwin RW. The new atypical antipsychotics. British Journal of Psychiatry 1994; 164:141-148.
82. Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. British Journal of Psychiatry (suppl.) 1992; 17:30-33.
83. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347:146-151.
84. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614.
85. Mortimer AM. Clozapine and schizophrenia. Schizophrenia Monitor 1991; 1:1-4.
86. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 1991; 324:746-754.
87. Ereshefsky L, Watanabe MD, Tran Johnson TK. Clozapine: an atypical antipsychotic agent. Clinical Pharmacology 1989; 8:691-709.
88. Marder SR, Van-Putten T. Who should receive clozapine? Archives of General Psychiatry 1988; 45:865-867.
89. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 1991; 17:247-261.
90. Kane JM. Acute treatment. In: Barnes TRE, ed. Antipsychotic drugs and their side-effects. London: Academic Press, 1993: 169-181.
91. McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 1991; 52:411-414.
92. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biological Psychiatry 1992; 32:270-280.
93. Kahn N, Freeman A, Juncos JL, Manning D, Watts RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991; 41:1699-1700.
94. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. Journal of Neuropsychiatry and Clinical Neurosciences 1993; 5:206-208.
95. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A Finnish epidemic. Acta Psychiatrica Scandinavica 1977; 56:241-248.
96. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99:S118-S121.
97. Andermann B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. European Journal of Clinical Pharmacology 1976; 11:199-201.
98. Alvir JMJ, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. Journal of Clinical Psychopharmacology 1994; 14-87-89.
99. Lieberman JA, Johns C, Kane JM, Rai K, Pisciotta AV, Saltz B, Howard A. Clozapine induced agranulocutosis: non-cross reactivity with other psychotropic drugs. Journal of Clinical Psychiatry 1988; 49:271-277.
100. Lieberman JA, Yunis J, Egea E, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 1990; 47:945-948.
101. Oren R, Granat E, Shtrussberg S, Matzner Y. Clozapine-induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. British Journal of Psychiatry 1993; 162:686-687.
102. Seeman P, Guan H, Van Tol HM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365:441-445.
103. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. Journal of Clinical Psychiatry 1994; 55:255-257.
104. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151:123-125.
105. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced stalorrhoea. British Journal of Psychiatry 1991; 159:166.
106. Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. Journal of Clinical Psychopharmacology 1992; 12:69-70.
107. Warner JP, Harvey CA, Barnes TRE Clozapine and urinary incontinence. International Clinical Psychopharmacology 1994; 9.207-209.
108. Aronowitz JS, Safferman AZ, Lieberman JA. Management of clozapine-induced enuresis. American Journal of Psychiatry 1995; 152:472.
109. Casey DE. Clozapine: neuroleptic drug-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99(suppl):S47-S53.
110. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine Journal of Clinical Psychiatry 1992; 53:439-442.
111. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 1991; 158:503-510.
112. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacology Series 1988, 5:74-93.
113. Coward DM. General pharmacology of clozapine. British Journal of Psychiatry (suppl.) 1992; 17:5-11
114. Anderson GD, Rebec GV. Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biological Psychiatry 1988; 23:497-506.
115. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajiboye PA. Clozapine withdrawal rebound psychosis. Psychopharmacology Bulletin 1988; 24 260-263.
116. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry 1989; 46:672.
117. Gerlach J. Future treatment of schizophrenia. Psychopharmacology Series 1988; 5:94-104.
118. Kohler C, Hall U, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica (suppl.) 1990; 82:27-36.
119. Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P, Kerr K, Zorbas A, Hill C, Stedman T, Johnson G, Leibert B, Copolov D, MacKenzie M, Dillenbeck C. The Australian multicentre double-blind comparative study of remoxipnde and thioridazine in schizophrenia. Acta Psychiatrica Scandinavica 1994; 90:358-365.
120. Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U. A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 1993; 87:114-117.
121. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophrenia Research 1992; 8:43-49.
122. Ley sen JE, Gommeren W, Eens A, de-Chaffoy CD, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 1992; 24:661-670.
123. Silverstone T, Levine S, Freeman HL, Dubini A. Zetidoline, a new antipsychotic: first controlled trial in acute schizophrenia. British Journal of Psychiatry 1984; 145:294-299.
124. Berlant JL. One more look at propranolol for the treatment of refractory schizophrenia. Schizophrenia Bulletin 1987; 13:705-714.
125. Pantelis C, Barnes TRE. Acute exacerbation of psychosis with buspirone? British Journal of Psychopharmacology 1993; 7:295-300.
126. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 36:349-352.
127. Delva NJ, Letemendia FJJ. Lithium treatment in schizophrenia and schrzoaffective disorders. In: Kerr A, Snaith P, eds. Contemporary issues in schizophrenia. London: Gaskell (Royal College of Psychiatrists), 1986:381-396.
128. Schulz SC, Kahn EM, Baker RW, Conley RR. Lithium and carbamazepine augmentation in treatment refractory schizophrenia In: Angrist B, Schulz SC, eds. The neuroleptic non-responsive patient: characterization and treatment. Washington; American Psychiatric Press, 1990:109-136.
129. Small JG, Kellams JJ, Milstein V, Moore JA. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry 1975; 132:1315-1317.
130. Growe GA, Crayton JW, Klass DB, Evans H, Stizich M. Lithium in chronic schizophrenia. American Journal of Psychiatry 1979; 136:454-455.
131. Carmen JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. Journal of Clinical Psychiatry 1981; 42:124-128.
132. Lerner Y, Mintzer Y, Shestatsky M. Lithium combined with haloperidol in schizophrenia patients. British Journal of Psychiatry 1988; 153:359-362.
133. Angst J, Weiss P, Grof P, Baastrup C, Schou M. Lithium prophylaxis in recurrent affective disorders. British Journal of Psychiatry 1970; 116:604-614.
134. Braden W, Fink EB, Quails B, Ho CK, Samuels WO. Lithium and chlorpromazine in psychotic inpatients. Psychiatry Research 1982; 7:69-81.
135. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol and irreversible brain damage. Journal of the American Medical Association 1974; 230:1283-1287.
136. Miller F, Menninger J. Lithium-neuroleptic neurotoxicity is dose-dependent. Journal of Clinical Psychopharmacology 1987; 7:89-91.
137. Ballenger JC. The clinical uses of carbamazepine in affective disorders. Journal of Clinical Psychiatry 1988; 49:13-21.
138. Elphick M. Clinical issues in the use of carbamazepine in psychiatry: a review. Psychological Medicine 1989; 19:591-604.
139. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Archives of General Psychiatry 1991; 48:448-452.
140. Hakola HP, Laulumaa VA. Carbamazepin in the treatment of violent schizophrenics. Lancet 1982; i:1358.
141. Luchins DJ. Carbamazepine for the violent psychiatric patient. Lancet 1983; i:766.
142. Hakola HP, Laulumaa VA. Carbamazepine in the treatment of violent schizophrenics. In: Emrich HM, Okuma T, Muller AA, eds Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984:204-207.
143. Neppe VM. Carbamazepine in nonresponsive psychosis. Journal of Clinical Psychiatry 1988; 49:22-30.
144. Rankel HW, Rankel LE. Carbamazepine in the treatment of catatonia. American Journal of Psychiatry 1988; 145:361-362.
145. Neppe VM. Carbamazepine as adjunctive treatment in non-epileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry 1983; 44:326-331.
146. Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacology Bulletin 1984; 20:572-584.
147. Luchins DJ. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacology Bulletin 1984; 20:569-571.
148. Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intelligence and Clinical Pharmacology 1987; 21:355-358.
149. Sramek J, Herrera J, Costa J, Heh C, Tran-Johnson T, Simpson G. A carbamazepine trial in chronic, treatment-refractory schizophrenia. American Journal of Psychiatry 1988; 145:748-750.
150. Okuma T, Yamashita I, Takashi R, Itoh H, Kurihara M, Otsuki R, Watanabe S, Hazamura H, Inanaga KA A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatrica Scandinavica 1989; 80:250-259.
151. Heh CWC, Potkin SG, Pickar D, Costa J, Herrera J, Sramek J, DeMet E. Serum homovallinic acid concentrations in carbarnazepine-treated chronic schizophrenics. Biological Psychiatry 1989; 25:639-641.
152. Carpenter WT Jr, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW, Waltrip RW, Breier A. Carbamazepine maintenance treatment in outpatient schizophrenics. Archives of General Psychiatry 1991; 48:69-72.
153. Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. American Journal of Psychiatry 1984; 141:1101-1102.
154. Yerevanian BI, Hodgman CH. A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder (letter). American Journal of Psychiatry 1985; 142:785-786.
155. Shukla S, Godwin CD, Long LE, Miller MC. Lithium-carbamazepine neurotoxicity and risk factors. American Journal of Psychiatry 1984; 141:1604-1606.
156. Elphick M, Lyons F, Cowen PJ. Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. Journal of Psychopharmacology 1988; 2:1-4.
157. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI. Does carbamazepine-induced reduction of plasma halopendol levels worsen psychotic symptoms? American Journal of Psychiatry 1985; 143:650-651.
158. Post RM. Time course of clinical effects of carbamazepine: Implications for mechanism of action. Journal of Clinical Psychiatry 1988; 49:35-48.
159. Post RM, Weiss SRB. Behavioural pharmacology of carbamazepine: differential effects on kindling. International Clinical Pharmacology 1987; 2:51-72.
160. Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 1987; 22:303-310.
161. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Archives of General Psychiatry 1984; 41:165-170.
162. Lingjaerde O, Engstrand E, Ellingsen P, Stylo DA, Robak OH. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial. Current Therapeutic Research 1979; 26:505-514.
163. Jimerson DC, Van Kammen DP, Post RM, Docherty JP, Bunney WEJ. Diazepam in schizophrenia: a preliminary double-blind trial. American Journal of Psychiatry 1982; 139:489-491.
164. Nestoros JN, Suranyi Cadotte BE, Spees RC, Schwartz G, Nair NP. Diazepam in high doses is effective in schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 1982; 6:513-516.
165. Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Archives of General Psychiatry 1988; 45:664-671.
166. Kellner R, Wilson RM, Muldawer MD, Pathak D. Anxiety in schizophrenia: the responses to chlordiazepoxide in an intensive design study. Archives of General Psychiatry 1994; 32:1246-1254.
167. Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Archives of General Psychiatry 1988; 45:655-659.
168. Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatrica Scandinavica 1987; 76:702-706.
169. Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacology Bulletin 1992; 28:291-295.
170. Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatrica Scandinavica 1982; 65:339-354.
171. Holden JM, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry 1968; 9:633-643.
172. Ruskin P, Averbukh I, Belmaker RH, Dasberg H. Benzodiazepines in chronic schizophrenia. Biological Psychiatry 1979; 14:557-558.
173. Wolkowitz OM, Rapaport MH, Pickar D. Benzodiazepine augmentation of neuroleptics. In: Angrist B, Schulz SC, eds. The neuroleptic nonresponsive patient: characterization and treatment. Washington: American Psychiatric Press, 1990:89-108.
174. Nestoros JN, Nair NPV, Pulman JR. Schwartz G, Bloom D. High doses of diazepam improve neuroleptic resistant chronic schizophrenic patients. Psychopathology 1983; 81:42-47.
175. Salzman C. The use of ECT in the treatment of schizophrenia. American Journal of Psychiatry 1980; 137:1032-1041.
176. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992; 18:515-542
177. Fink M. Clozapine and electroconvulsive therapy. Archives of General Psychiatry 1990; 47:290-291.
178. Friedel RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacology Bulletin 1986; 22:928-930.
179. Gujavarty K, Greenberg LB, Fink M. Electroconvulsive therapy and neuroleptic medication in therapy-resistant positive symptom psychosis. Convulsive Therapy 1987; 3:185-195.
180. Milstein V, Small JG, Miller MJ, Sharpley PH, Small IF. Mechanisms of action of ECT: schizophrenia and schizoaffective disorder. Biological Psychiatry 1990; 27:1282-1292.
181. Klapheke MM. Follow-up on clozapine and ECT. Convulsive Therapy 1991; 7:303-305.
182. Landy DA. Combined use of clozapine and electroconvulsive therapy. Convulsive Therapy 1991; 7:218-221.
183. Safferman AZ, Munne R. Combining clozapine with ECT. Convulsive Therapy 1992; 8:141-143.
184. Frankenburg FR, Suppes T, McLean PE. Combined clozapine and electroconvulsive therapy. Convulsive Therapy 1993; 9:176-180.